A detailed history of Prudential Financial Inc transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Prudential Financial Inc holds 305,337 shares of TGTX stock, worth $9.42 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
305,337
Previous 85,589 256.75%
Holding current value
$9.42 Million
Previous $1.52 Million 369.19%
% of portfolio
0.01%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$17.21 - $25.28 $3.78 Million - $5.56 Million
219,748 Added 256.75%
305,337 $7.14 Million
Q2 2024

Aug 13, 2024

BUY
$13.32 - $19.19 $999,466 - $1.44 Million
75,035 Added 710.96%
85,589 $1.52 Million
Q1 2024

May 14, 2024

SELL
$13.02 - $21.3 $13 - $21
-1 Reduced 0.01%
10,554 $160,000
Q4 2023

Feb 13, 2024

BUY
$6.68 - $18.81 $2,204 - $6,207
330 Added 3.23%
10,555 $180,000
Q3 2023

Nov 13, 2023

SELL
$8.36 - $26.5 $376,467 - $1.19 Million
-45,032 Reduced 81.5%
10,225 $85,000
Q2 2023

Aug 11, 2023

SELL
$15.48 - $35.0 $1.37 Million - $3.09 Million
-88,338 Reduced 61.52%
55,257 $1.37 Million
Q1 2023

May 12, 2023

BUY
$10.23 - $19.34 $1.47 Million - $2.78 Million
143,595 New
143,595 $2.16 Million
Q1 2022

May 13, 2022

SELL
$7.81 - $20.45 $73,343 - $192,045
-9,391 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$15.2 - $35.51 $16,735 - $39,096
-1,101 Reduced 10.49%
9,391 $327,000
Q3 2021

Nov 15, 2021

SELL
$21.78 - $40.45 $15,093 - $28,031
-693 Reduced 6.2%
10,492 $328,000
Q2 2021

Aug 16, 2021

BUY
$32.5 - $48.96 $10,075 - $15,177
310 Added 2.85%
11,185 $434,000
Q1 2021

May 12, 2021

BUY
$41.61 - $54.3 $23,551 - $30,733
566 Added 5.49%
10,875 $524,000
Q4 2020

Feb 16, 2021

BUY
$25.27 - $54.9 $16,703 - $36,288
661 Added 6.85%
10,309 $536,000
Q3 2020

Aug 05, 2021

BUY
$18.49 - $27.24 $178,391 - $262,811
9,648 New
9,648 $259,000

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $4.48B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Prudential Financial Inc Portfolio

Follow Prudential Financial Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prudential Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Prudential Financial Inc with notifications on news.